Contact
Please use this form to send email to PR contact of this press release:
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
TO:
Please use this form to send email to PR contact of this press release:
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
TO: